GlaxoSmithkline Pharmaceuticals Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported revenue from operations of INR 7,039.1 million, profit before exceptional items and tax of INR 1,043.8 million, profit before tax of INR 1,043.8 million and profit for the period of INR 896.9 million or INR 10.6 per basic and diluted share compared to revenue from operations of INR 7,063.8 million, profit before exceptional items and tax of INR 602.7 million, profit before tax of INR 781.6 million and profit for the period of INR 529.5 million or INR 6.3 per basic and diluted share reported in the same period last year. For the nine months, the company reported revenue from operations of INR 21,472.6 million, profit before exceptional items and tax of INR 3,601.7 million, profit before tax of INR 3,779.7 million and profit for the period of INR 2,464.3 million or INR 29.1 per basic and diluted share compared to revenue from operations of INR 22,108.3 million, profit before exceptional items and tax of INR 3,215.1 million, profit before tax of INR 3,413.8 million and profit for the period of INR 2,240.7 million or INR 26.5 per basic and diluted share reported in the same period last year.